Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
83 studies found for:    avid
Show Display Options
Rank Status Study
1 Recruiting MIBG Therapy for Patients With MIBG Avid Tumors
Condition: MIBG Avid Tumors
Intervention: Drug: MIBG
2 Completed Clinical Study of Asahi ViE Dialyzer in Canada
Condition: Kidney Failure, Chronic
Intervention: Device: ViE-21
3 Unknown  11C-Acetate PET/CT Non-FDG-Avid Tumors
Conditions: Soft Tissue Sarcomas;   Thyroid Cancer;   Lung Cancer;   Indolent Lymphoma;   Neuroendocrine Tumors;   GIST;   Uterine Malignancies;   Carcinoma, Hepatocellular;   Carcinoma, Lobular;   Teratoma
4 Completed Augmenting 18F-AV-1451 Dosimetry Estimates
Condition: Alzheimer's Disease
Intervention: Drug: 18F-AV-1451
5 Withdrawn The Effects of Active VItamin D on Left Atrial Volume Index
Condition: Heart Failure
Intervention: Drug: Paricalcitol
6 Recruiting Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Conditions: Alzheimer Disease;   Mild Cognitive Impairment;   Neurodegenerative Diseases
Intervention: Drug: Florbetapir F 18
7 Recruiting 18F-AV-1451 Autopsy Study
Condition: Alzheimer's Disease
Intervention: Drug: 18F-AV-1451
8 Completed Antiarrhythmics Versus Implantable Defibrillators (AVID)
Conditions: Arrhythmia;   Cardiovascular Diseases;   Death, Sudden, Cardiac;   Heart Diseases;   Tachycardia, Ventricular;   Ventricular Fibrillation
Interventions: Device: defibrillators, implantable;   Drug: amiodarone amiodarone;   Drug: sotalol
9 Recruiting PET-MRI in Diagnosing Patients With Cancer, Cardiac Diseases, or Neurologic Diseases
Conditions: Cardiac Disease;   Dementia;   Inflammatory Disease;   Fever of Unknown Origin;   Vasculitis;   Osteomyelitis;   FDG Avid Cancers
Interventions: Procedure: positron emission tomography;   Procedure: computed tomography;   Procedure: magnetic resonance imaging
10 Recruiting Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer
Conditions: Poorly Differentiated Thyroid Gland Carcinoma;   Recurrent Thyroid Gland Carcinoma;   Stage IVA Thyroid Gland Follicular Carcinoma;   Stage IVA Thyroid Gland Papillary Carcinoma;   Stage IVB Thyroid Gland Follicular Carcinoma;   Stage IVB Thyroid Gland Papillary Carcinoma;   Stage IVC Thyroid Gland Follicular Carcinoma;   Stage IVC Thyroid Gland Papillary Carcinoma
Interventions: Radiation: Iodine I-131;   Other: Laboratory Biomarker Analysis;   Other: Placebo;   Drug: Selumetinib
11 Completed Exercise in Asymptomatic Pre-Alzheimer's Disease Pilot Study
Condition: Alzheimer's Disease Prevention
Intervention: Behavioral: Aerobic vs. Non-Aerobic exercise
12 Active, not recruiting Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
Conditions: Disseminated Neuroblastoma;   Ganglioneuroblastoma;   Localized Resectable Neuroblastoma;   Localized Unresectable Neuroblastoma;   Regional Neuroblastoma;   Stage 4S Neuroblastoma
Interventions: Drug: cyclophosphamide;   Drug: topotecan hydrochloride;   Drug: cisplatin;   Drug: etoposide phosphate;   Drug: vincristine sulfate;   Drug: doxorubicin hydrochloride;   Radiation: iobenguane I 131;   Procedure: therapeutic conventional surgery;   Drug: busulfan;   Drug: melphalan;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: in vitro-treated peripheral blood stem cell transplantation;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: external beam radiation therapy;   Radiation: intensity-modulated radiation therapy;   Drug: isotretinoin;   Other: pharmacological study;   Other: questionnaire administration;   Other: laboratory biomarker analysis
13 Recruiting PET/CT-Assessment of Liver Tumor Ablation
Conditions: Liver Tumor;   Liver Neoplasms
Interventions: Radiation: N-13 ammonia;   Device: PET/CT scanner
14 Completed
Has Results
Evaluation of Reader Training Processes
Condition: Alzheimer's Disease
Intervention: Drug: florbetapir F 18
15 Completed
Has Results
Imaging Characteristics of Florbetapir 18F in Patients With Frontotemporal Dementia, Alzheimer's Disease and Normal Controls.
Conditions: Alzheimer's Disease;   Frontotemporal Dementia
Interventions: Drug: florbetapir 18F;   Drug: 18F-FDG
16 Terminated A Phase 0, Open Label, Multi-center Exploratory and Safety Study of [F-18]T807
Conditions: Alzheimers Disease;   AD
Intervention: Radiation: [F18] T807
17 Terminated A Phase 0, Open Label, Multi-Center, Exploratory and Safety Study of [F-18]T808
Condition: Alzheimers Disease
Intervention: Radiation: [F18] T808
18 Completed Quantitative 18F-AV-133 PET Imaging in Subjects With Diabetes and Healthy Controls
Condition: Type 2 Diabetes
Interventions: Drug: 18F-AV-133;   Drug: 10% Arginine Hydrochloride-R-Gene 10
19 Completed
Has Results
Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline
Condition: Alzheimer's Disease
Intervention: Drug: florbetapir (18F)
20 Completed
Has Results
A Phase II Trial of Florbetapir (18F) Positron Emission Tomography (PET) Imaging in Japan of Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)
Conditions: Alzheimer's Disease;   Mild Cognitive Impairment
Intervention: Drug: florbetapir (18F)

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years